Table 3 Comparison of characteristics between patients with and without exacerbations
|  | Exacerbations ≥ 1 (n = 121) | No Exacerbations (n = 107) | P Value |
|---|---|---|---|
Age (years) | 55.0 (43.0–63.0) | 48.0 (37.0–59.0) | 0.003 |
Sex, female | 56 (46.3%) | 52 (48.6%) | 0.158 |
Age of diagnosis (years) | 41.0 (21.0–52.0) | 37.0 (22.5–50.0) | 0.757 |
Duration of asthma | 9.0 (5.0–22.0) | 6.0 (3.0–15.0) | 0.005 |
Pre-bronchodilator FEV1% pred(n = 219) | 61.9 ± 23.5 | 74.9 ± 22.9 | < 0.001 |
Pre-bronchodilator FEV1/FVC (%) (n = 221) | 60.2 ± 13.7 | 69.1 ± 13.9 | < 0.001 |
Post-bronchodilator FEV1% pred (n = 184) | 70.3 ± 22.6 | 80.8 ± 22.2 | 0.002 |
Post-bronchodilator FEV1/FVC (%) (n = 189) | 65.1 (59.5–75.2) | 73.5 (64.0-83.5) | < 0.001 |
FENO, ppb (n = 161) | 41.0 (23.8–73.8) | 40.0 (24.0–83.0) | 0.874 |
Blood neutrophil (%) (n = 159) | 57.7 (50.9–66.3) | 56.2 (50.7–62.4) | 0.325 |
Blood neutrophil (/ul) (n = 157) | 4100.0 (3400.0-5500.0) | 3900.0 (3225.0-5175.0) | 0.325 |
Blood eosinophil (%) (n = 172) | 3.1 (1.5–6.3) | 4.6 (2.1–8.5) | 0.079 |
Blood eosinophil (/ul) (n = 168) | 205.0 (122.0-367.5) | 315.0 (140.0-632.5) | 0.044 |
Total IgE, IU/ml (n = 186) | 202.0 (74.2–405.0) | 282.0 (128.0-533.0) | 0.075 |
ACT score (n = 198) | 19.0 (18.0–21.0) | 21.0 (19.0–23.0) | 0.001 |
AQLQ score (n = 130) | 4.2 ± 1.2 | 4.9 ± 1.3 | 0.001 |
GINA step 5 | 56 (46.3%) | 40 (37.4%) | 0.003 |
Number of comorbidities (n = 183) | Â | Â | 0.116 |
0 | 10 (10.5%) | 13 (14.8%) | Â |
1 | 30 (31.6%) | 39 (44.3%) | Â |
2 | 32 (33.7%) | 24 (27.3%) | Â |
≥ 3 | 23 (24.2%) | 12 (13.6%) |  |